



## Clinical trial results:

### Protocol I1F-MC-RHBY

## A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients with Axial Spondyloarthritis

### Summary

EudraCT number	2016-002634-69
Trial protocol	ES HU NL FI PL AT DE IT
Global end of trial date	

### Results information

Result version number	v1
This version publication date	10 June 2021
First version publication date	10 June 2021

### Trial information

#### Trial identification

Sponsor protocol code	I1F-MC-RHBY
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03129100
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 16181

Notes:

### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	26 May 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 May 2020
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 May 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 34
Country: Number of subjects enrolled	Romania: 5
Country: Number of subjects enrolled	Hungary: 7
Country: Number of subjects enrolled	United States: 61
Country: Number of subjects enrolled	Czechia: 88
Country: Number of subjects enrolled	Japan: 22
Country: Number of subjects enrolled	United Kingdom: 12
Country: Number of subjects enrolled	Spain: 10
Country: Number of subjects enrolled	Russian Federation: 66
Country: Number of subjects enrolled	Canada: 11
Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	Korea, Republic of: 81
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Taiwan: 44
Country: Number of subjects enrolled	Finland: 9
Country: Number of subjects enrolled	Brazil: 23
Country: Number of subjects enrolled	Poland: 160
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Mexico: 104
Country: Number of subjects enrolled	Israel: 10
Country: Number of subjects enrolled	France: 10

Country: Number of subjects enrolled	Germany: 9
Worldwide total number of subjects	773
EEA total number of subjects	317

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	737
From 65 to 84 years	36
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Lead-In (Period 1): 24 weeks (Week 0 to Week 24)

Extension Period including Double-Blind, Placebo-Controlled, Randomized Withdrawal-Retreatment (RWR) (Period 2): 40 weeks (Week 24 to Week 64).

Data beyond week 64 are still being collected and will be reported after Study Completion.

### Pre-assignment

Screening details:

In Period 2, participants (pts) who did not achieve sustained remission were assigned to Group A, pts who did achieve sustained remission were assigned to Group B (Randomized Withdrawal Extension(RWE)) and were randomized 2:1 to either IXE or Placebo. pts who experienced a flare in group B were retreated with IXE in Retreatment Extension Period.

### Period 1

Period 1 title	Lead-In Period (Period 1)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
Arm title	IXE80Q4W-Lead-in Period

Arm description:

Participants received 80 milligram (mg) of Ixekizumab (IXE) subcutaneously (SC) every four weeks (Q4W) for up to week 24.

Arm type	Experimental
Investigational medicinal product name	IXE80Q4W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every four weeks.

Arm title	IXE80Q2W-Lead-in Period
-----------	-------------------------

Arm description:

Participants received 80 mg of Ixekizumab subcutaneously every two weeks (Q2W) for up to week 24.

Arm type	Experimental
Investigational medicinal product name	IXE80Q2W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every two weeks.

Number of subjects in period 1	IXE80Q4W-Lead-in Period	IXE80Q2W-Lead-in Period
Started	350	423
Completed	335	406
Not completed	15	17
Consent withdrawn by subject	8	8
Adverse event, non-fatal	2	6
Lost to follow-up	2	-
Check with team	-	1
Lack of efficacy	3	2

## Period 2

Period 2 title	Extension Period (Period 2A)
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

## Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	IXE80Q4W-Group A Extension Period

### Arm description:

Participants continued to receive uninterrupted Ixekizumab 80 mg Q4W subcutaneous dose during the extension period.

Arm type	Placebo
Investigational medicinal product name	IXE80Q4W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

### Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every four weeks.

<b>Arm title</b>	IXE80Q2W-Group A Extension Period
------------------	-----------------------------------

### Arm description:

Participants continued to receive uninterrupted Ixekizumab 80 mg Q2W subcutaneous dose during the extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q2W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

### Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every two weeks.

Investigational medicinal product name	IXE80Q2W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every two weeks.

<b>Arm title</b>	IXE80Q4W-Group B-Randomized Withdrawal Extension Period
------------------	---

Arm description:

Participants in the Ixekizumab 80 mg Q4W treatment group (Lead-in) were re randomized to receive Ixekizumab 80 mg Q4W subcutaneous dose at Week 24 in the randomized withdrawal extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q4W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every four weeks.

<b>Arm title</b>	IXE80Q2W-Group B-Randomized Withdrawal Extension Period
------------------	---

Arm description:

Participants in the Ixekizumab 80 mg Q2W treatment group (Lead-in) were re randomized to receive subcutaneous dose of Ixekizumab 80 mg Q2W at Week 24 in the randomized withdrawal extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q2W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 80 mg of Ixekizumab subcutaneously every two weeks.

<b>Arm title</b>	Placebo-Group B-Randomized Withdrawal Extension Period
------------------	--

Arm description:

Participants were re-randomized to receive subcutaneous dose of placebo at Week 24 in the randomized withdrawal extension period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants were randomized to receive subcutaneous injection of placebo.

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Baseline analysis population is based on efficacy population of all randomized participants (Extension Period).

Number of subjects in period 2	IXE80Q4W-Group A Extension Period	IXE80Q2W-Group A Extension Period	IXE80Q4W-Group B- Randomized Withdrawal Extension Period
Started	255	318	48
Completed	234	312	42
Not completed	21	6	6
Adverse event, serious fatal	1	-	-
Consent withdrawn by subject	13	5	1
Physician decision	1	-	-
Adverse event, non-fatal	2	1	-
Lost to follow-up	2	-	-
Experienced Flare and retreated	-	-	5
Lack of efficacy	2	-	-

Number of subjects in period 2	IXE80Q2W-Group B- Randomized Withdrawal Extension Period	Placebo-Group B- Randomized Withdrawal Extension Period
Started	54	53
Completed	45	32
Not completed	9	21
Adverse event, serious fatal	-	-
Consent withdrawn by subject	1	2
Physician decision	-	-
Adverse event, non-fatal	2	-
Lost to follow-up	-	-
Experienced Flare and retreated	6	19
Lack of efficacy	-	-

### Period 3

Period 3 title	Retreatment Extension Period (Period 2)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	IXE80Q2W/IXE80Q2W-retreatment Extension Period
------------------	--

**Arm description:**

Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q2W during the retreatment extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q2W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants received 80 mg of Ixekizumab subcutaneously every two weeks.

<b>Arm title</b>	IXE80Q4W/IXE80Q4W-Retreatment Extension Period
------------------	--

**Arm description:**

Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q4W during the retreatment extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q4W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants received 80 mg of Ixekizumab subcutaneously every four weeks.

<b>Arm title</b>	PBO/IXE80Q2W-Retreatment Extension Period
------------------	---

**Arm description:**

Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q2W during the retreatment extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q2W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants received 80 mg of Ixekizumab subcutaneously every two weeks.

<b>Arm title</b>	PBO/IXE80Q4W-Retreatment Extension Period
------------------	---

**Arm description:**

Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q4W during the retreatment extension period.

Arm type	Experimental
Investigational medicinal product name	IXE80Q4W
Investigational medicinal product code	
Other name	Ixekizumab; LY2439821
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants received 80 mg of Ixekizumab subcutaneously every four weeks.



<b>Number of subjects in period 3</b>	IXE80Q2W/IXE80Q2W-retreatment Extension Period	IXE80Q4W/IXE80Q4W-Retreatment Extension Period	PBO/IXE80Q2W-Retreatment Extension Period
Started	6	5	9
Completed	6	5	8
Not completed	0	0	1
Consent withdrawn by subject	-	-	1

<b>Number of subjects in period 3</b>	PBO/IXE80Q4W-Retreatment Extension Period
Started	10
Completed	10
Not completed	0
Consent withdrawn by subject	-

## Baseline characteristics

### Reporting groups<sup>[1]</sup>

Reporting group title	IXE80Q4W-Group A Extension Period
-----------------------	-----------------------------------

Reporting group description:

Participants continued to receive uninterrupted Ixekizumab 80 mg Q4W subcutaneous dose during the extension period.

Reporting group title	IXE80Q2W-Group A Extension Period
-----------------------	-----------------------------------

Reporting group description:

Participants continued to receive uninterrupted Ixekizumab 80 mg Q2W subcutaneous dose during the extension period.

Reporting group title	IXE80Q4W-Group B-Randomized Withdrawal Extension Period
-----------------------	---

Reporting group description:

Participants in the Ixekizumab 80 mg Q4W treatment group (Lead-in) were re randomized to receive Ixekizumab 80 mg Q4W subcutaneous dose at Week 24 in the randomized withdrawal extension period.

Reporting group title	IXE80Q2W-Group B-Randomized Withdrawal Extension Period
-----------------------	---

Reporting group description:

Participants in the Ixekizumab 80 mg Q2W treatment group (Lead-in) were re randomized to receive subcutaneous dose of Ixekizumab 80 mg Q2W at Week 24 in the randomized withdrawal extension period.

Reporting group title	Placebo-Group B-Randomized Withdrawal Extension Period
-----------------------	--

Reporting group description:

Participants were re-randomized to receive subcutaneous dose of placebo at Week 24 in the randomized withdrawal extension period.

Notes:

[1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.

Justification: Baseline characteristics presented only for treatment group.

Reporting group values	IXE80Q4W-Group A Extension Period	IXE80Q2W-Group A Extension Period	IXE80Q4W-Group B-Randomized Withdrawal Extension Period
Number of subjects	255	318	48
Age categorical Units: Subjects			
<=18 years	0	0	0
Between 18 and 65 years	240	302	48
>=65 years	15	16	0
Gender categorical Units: Subjects			
Female	68	95	10
Male	187	223	38
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	61	86	7
Not Hispanic or Latino	166	204	31
Unknown or Not Reported	28	28	10
Race (NIH/OMB) Units: Subjects			

American Indian or Alaska Native	14	11	2
Asian	54	50	15
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	2	0
White	183	247	31
More than one race	3	8	0
Unknown or Not Reported	1	0	0
Region of Enrollment			
Units: Subjects			
Argentina	11	18	1
Romania	1	3	0
Hungary	3	2	1
United States	14	30	1
Czechia	37	35	5
Japan	7	9	1
United Kingdom	4	6	0
Spain	5	4	0
Russia	16	30	6
Canada	3	2	1
Netherlands	0	2	0
South Korea	28	23	10
Austria	1	1	0
Taiwan	17	16	3
Finland	0	5	0
Brazil	7	16	0
Poland	50	67	13
Italy	0	1	0
Mexico	40	38	5
Israel	5	3	0
France	4	4	0
Germany	2	3	1

Reporting group values	IXE80Q2W-Group B- Randomized Withdrawal Extension Period	Placebo-Group B- Randomized Withdrawal Extension Period	Total
Number of subjects	54	53	728
Age categorical			
Units: Subjects			
<=18 years	0	0	0
Between 18 and 65 years	53	52	695
>=65 years	1	1	33
Gender categorical			
Units: Subjects			
Female	14	15	202
Male	40	38	526
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	14	11	179
Not Hispanic or Latino	35	39	475
Unknown or Not Reported	5	3	74
Race (NIH/OMB)			

Units: Subjects			
American Indian or Alaska Native	5	4	36
Asian	15	13	147
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	2
White	31	35	527
More than one race	3	1	15
Unknown or Not Reported	0	0	1
Region of Enrollment			
Units: Subjects			
Argentina	1	2	33
Romania	1	0	5
Hungary	1	0	7
United States	3	2	50
Czechia	4	4	85
Japan	3	1	21
United Kingdom	1	0	11
Spain	1	0	10
Russia	7	6	65
Canada	0	2	8
Netherlands	0	0	2
South Korea	7	8	76
Austria	1	0	3
Taiwan	5	2	43
Finland	1	2	8
Brazil	0	0	23
Poland	7	13	150
Italy	0	0	1
Mexico	11	8	102
Israel	0	1	9
France	0	0	8
Germany	0	2	8

## End points

### End points reporting groups

Reporting group title	IXE80Q4W-Lead-in Period
Reporting group description: Participants received 80 milligram (mg) of Ixekizumab (IXE) subcutaneously (SC) every four weeks (Q4W) for up to week 24.	
Reporting group title	IXE80Q2W-Lead-in Period
Reporting group description: Participants received 80 mg of Ixekizumab subcutaneously every two weeks (Q2W) for up to week 24.	
Reporting group title	IXE80Q4W-Group A Extension Period
Reporting group description: Participants continued to receive uninterrupted Ixekizumab 80 mg Q4W subcutaneous dose during the extension period.	
Reporting group title	IXE80Q2W-Group A Extension Period
Reporting group description: Participants continued to receive uninterrupted Ixekizumab 80 mg Q2W subcutaneous dose during the extension period.	
Reporting group title	IXE80Q4W-Group B-Randomized Withdrawal Extension Period
Reporting group description: Participants in the Ixekizumab 80 mg Q4W treatment group (Lead-in) were re randomized to receive Ixekizumab 80 mg Q4W subcutaneous dose at Week 24 in the randomized withdrawal extension period.	
Reporting group title	IXE80Q2W-Group B-Randomized Withdrawal Extension Period
Reporting group description: Participants in the Ixekizumab 80 mg Q2W treatment group (Lead-in) were re randomized to receive subcutaneous dose of Ixekizumab 80 mg Q2W at Week 24 in the randomized withdrawal extension period.	
Reporting group title	Placebo-Group B-Randomized Withdrawal Extension Period
Reporting group description: Participants were re-randomized to receive subcutaneous dose of placebo at Week 24 in the randomized withdrawal extension period.	
Reporting group title	IXE80Q2W/IXE80Q2W-retreatment Extension Period
Reporting group description: Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q2W during the retreatment extension period.	
Reporting group title	IXE80Q4W/IXE80Q4W-Retreatment Extension Period
Reporting group description: Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q4W during the retreatment extension period.	
Reporting group title	PBO/IXE80Q2W-Retreatment Extension Period
Reporting group description: Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q2W during the retreatment extension period.	
Reporting group title	PBO/IXE80Q4W-Retreatment Extension Period
Reporting group description: Participants in Group B who experienced a flare were retreated with subcutaneous dose of Ixekizumab 80 mg Q4W during the retreatment extension period.	

Subject analysis set title	Combined IXE
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 80 mg of Ixekizumab subcutaneously (SC) every four weeks (Q4W) and every two weeks (Q2W) during the randomized withdrawal extension period.	
Subject analysis set title	Placebo
Subject analysis set type	Per protocol
Subject analysis set description: Participants received placebo subcutaneously during the randomized withdrawal extension period.	
Subject analysis set title	IXE80Q4W
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 80 mg of Ixekizumab subcutaneously (SC) every four weeks (Q4W) during the randomized withdrawal extension period.	
Subject analysis set title	IXE80Q2W
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 80 mg of Ixekizumab subcutaneously (SC) every two weeks (Q2W) during the randomized withdrawal extension period.	

### **Primary: Percentage of Participants who do not Experience a Flare (Combined Ixekizumab Treatment)**

End point title	Percentage of Participants who do not Experience a Flare (Combined Ixekizumab Treatment)
End point description: A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS $\geq 2.1$ ) at 2 consecutive visits, or ASDAS $> 3.5$ at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: $0.121 \times \text{total back pain} + 0.110 \times \text{patient global} + 0.073 \times \text{peripheral pain/swelling} + 0.058 \times \text{duration of morning stiffness} + 0.579 \times \ln(\text{CRP} + 1)$ . (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity. APD: pts who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR.	
End point type	Primary
End point timeframe: Week 64	

End point values	Combined IXE	Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	102	53		
Units: Percentage of participants				
number (not applicable)	83.3	54.7		

### **Statistical analyses**

Statistical analysis title	Who do not Experience a Flare (Combined IXE)
Comparison groups	Combined IXE v Placebo

Number of subjects included in analysis	155
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.03
upper limit	9.35

## Secondary: Percentage of Participants who do not Experience a Flare

End point title	Percentage of Participants who do not Experience a Flare
End point description:	
<p>A flare is defined as ASDAS <math>\geq 2.1</math> at 2 consecutive visits or ASDAS <math>&gt; 3.5</math> at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sensitivity C-reactive protein (CRP) as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: <math>0.121 \times \text{total back pain} + 0.110 \times \text{patient global} + 0.073 \times \text{peripheral pain/swelling} + 0.058 \times \text{duration of morning stiffness} + 0.579 \times \ln(\text{CRP} + 1)</math> (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.</p> <p>APD: pts who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using NRI.</p>	
End point type	Secondary
End point timeframe:	
Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of participants				
number (not applicable)	54.7	83.3	83.3	

## Statistical analyses

Statistical analysis title	Participants Who do Not Experience a Flare
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.66
upper limit	11.03

<b>Statistical analysis title</b>	Participants Who do Not Experience a Flare
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.77
upper limit	11.02

## Secondary: Change from Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)

End point title	Change from Baseline in Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)
-----------------	---

### End point description:

The mSASSS is a four-point scoring system for lateral radiographs of the lumbar and cervical spine and has been shown to reliably track disease progression over time, where: 0 = normal; 1 = sclerosis, squaring or erosion; 2 = syndesmophyte; 3 = bony bridge.

By the scoring system of mSASSS of the spinal x-rays, a total of 24 sites were scored on the lateral cervical and lumbar spine: the anterior corners of the vertebrae from lower border of C2 to upper border T1 (inclusive), and from lower border of T12 to upper border of S1 (inclusive). Each corner was scored from 0 to 3, resulting in a range from 0 [no change] to 72 [progression].

APD: Ixekizumab structure population who have been treated with ixekizumab for at least 24 months.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, 2 Years (108 Weeks)



End point values	Combined IXE	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	230	115	115	
Units: Units on a Scale				
arithmetic mean (standard deviation)	0.32 (± 1.779)	0.41 (± 2.102)	0.23 (± 1.387)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response

End point title	Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS)20 Response
End point description:	
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in ≥3 of 4 domains, and no worsening of ≥20% and ≥1 unit in the remaining domain.	
Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active).	
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).	
Bath Ankylosing Spondylitis Functional Index (BASFI): Participant asked to rate the difficulty associated with 10 individual basic functional activities, response measured on NRS (range 0 to 10) with a higher score indicating worse function.	
Inflammation based on mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 & Q6 (mean of intensity & duration of stiffness): Score ranges from "0" (none) and "10" (very severe).	
APD: Participants who achieved a state of sustained remission and randomized to 40-week DBPC RWR period.	
End point type	Secondary
End point timeframe:	
Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of participants				
number (not applicable)	50.9	81.3	81.5	

## Statistical analyses

Statistical analysis title	ASAS20 response
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.78
upper limit	11.41

<b>Statistical analysis title</b>	ASAS20 response
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.88
upper limit	11.31

## Secondary: Percentage of Participants Achieving an ASAS40 Response

End point title	Percentage of Participants Achieving an ASAS40 Response
End point description:	
ASAS40 is defined as a $\geq 40\%$ improvement and an absolute improvement from baseline of $\geq 2$ units (range of 0 to 10) in at least 3 of the following 4 domains without any worsening in the remaining domain. The following ASAS domains are used:	
Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active).	
Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).	
BASFI: Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function.	
Inflammation based on mean of BASDAI Q5 & Q6 (mean of intensity & duration of stiffness): Score ranges from "0" (none) and "10" (very severe).	
APD: Participants who achieved a state of sustained remission and were randomized to 40-week DBPLC RWR period.	
End point type	Secondary
End point timeframe:	
Week 64	

<b>End point values</b>	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of Participants				
number (not applicable)	43.4	79.2	79.6	

### Statistical analyses

<b>Statistical analysis title</b>	ASAS40 Response
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	5.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.11
upper limit	12.69

<b>Statistical analysis title</b>	ASAS40 Response
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	5.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.2
upper limit	12.47

### Secondary: Percentage of Participants with Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) $\geq 1.1$ Units

End point title	Percentage of Participants with Change of Ankylosing Spondylitis Disease Activity Score (ASDAS) $\geq 1.1$ Units
End point description:	
<p>ASDAS is a composite index to assess disease activity in AS.</p> <p>The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation: <math>0.121 \times \text{total back pain} + 0.110 \times \text{patient global} + 0.073 \times \text{peripheral pain/swelling} + 0.058 \times \text{duration of morning stiffness} + 0.579 \times \ln(\text{CRP} + 1)</math>. (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.</p> <p>APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the nonresponder imputation (NRI) method.</p>	
End point type	Secondary
End point timeframe:	
Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of participants				
number (not applicable)	45.3	79.2	74.1	

### Statistical analyses

<b>Statistical analysis title</b>	ASDAS $\geq 1.1$ Units
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.9
upper limit	11.17

<b>Statistical analysis title</b>	ASDAS $\geq 1.1$ Units
Comparison groups	IXE80Q2W v Placebo

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	3.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.56
upper limit	8.09

### Secondary: Percentage of Participants with Inactive Disease on the ASDAS (<1.3 Units)

End point title	Percentage of Participants with Inactive Disease on the ASDAS (<1.3 Units)
-----------------	--

End point description:

ASDAS is a composite index to assess disease activity in AS.

The parameters used for the ASDAS (with CRP as acute phase reactant) are total back pain, patient global, peripheral pain/swelling, duration of morning stiffness and CRP in mg/L. The ASDAScrp is calculated with the following equation:  $0.121 \times \text{total back pain} + 0.110 \times \text{patient global} + 0.073 \times \text{peripheral pain/swelling} + 0.058 \times \text{duration of morning stiffness} + 0.579 \times \ln(\text{CRP} + 1)$ . (CRP is in mg/liter, the range of other variables is from 0(normal) to 10(very severe); Ln represents the natural logarithm). Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher the score worse the disease activity.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the nonresponder imputation (NRI) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of participants				
number (not applicable)	24.5	60.4	53.7	

### Statistical analyses

Statistical analysis title	ASDAS (<1.3 Units)
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.07
upper limit	11.72

<b>Statistical analysis title</b>	ASDAS (<1.3 Units)
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	3.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.57
upper limit	8.32

## Secondary: Change from Baseline in the Individual Components of the ASAS Criteria

End point title	Change from Baseline in the Individual Components of the ASAS Criteria
-----------------	--

End point description:

Patient Global: How active was your spondylitis on average during the last week? score ranges 0 (not active) to 10 (very active).

Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain).

BASFI: Participant asked to rate the difficulty associated with 10 individual basic functional activities. Participant response was captured using Numeric Rating Scale (NRS) (range 0 to 10) with a higher score indicating worse function. Inflammation based on Q5 & Q6 mean of BASDAI (mean of intensity & duration of stiffness): Score ranges from "0" (none) and "10" (very severe). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week DBPC RWR. Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Units on a scale				
least squares mean (standard error)				
Patient Global	-3.0 (± 0.36)	-5.1 (± 0.38)	-5.0 (± 0.36)	
Spinal Pain	-3.0 (± 0.36)	-5.1 (± 0.39)	-4.8 (± 0.37)	
BASFI	-2.79 (± 0.301)	-4.35 (± 0.316)	-4.19 (± 0.301)	
Inflammation	-3.03 (± 0.317)	-5.20 (± 0.336)	-4.83 (± 0.319)	

## Statistical analyses

Statistical analysis title	ASAS Criteria
Statistical analysis description:	
Patient Global	
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority <sup>[1]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	-1.1
Variability estimate	Standard error of the mean
Dispersion value	0.51

Notes:

[1] - Patient Global

Statistical analysis title	ASAS Criteria
Statistical analysis description:	
Patient Global	
Comparison groups	IXE80Q2W v Placebo

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority <sup>[2]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	-1
Variability estimate	Standard error of the mean
Dispersion value	0.49

Notes:

[2] - Patient Global

<b>Statistical analysis title</b>	ASAS Criteria
Statistical analysis description:	
Spinal Pain	
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	-1
Variability estimate	Standard error of the mean
Dispersion value	0.51

Notes:

[3] - Spinal Pain

<b>Statistical analysis title</b>	ASAS Criteria
Statistical analysis description:	
Spinal Pain	
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority <sup>[4]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.8



Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	-0.8
Variability estimate	Standard error of the mean
Dispersion value	0.49

Notes:

[4] - Spinal Pain

<b>Statistical analysis title</b>	ASAS Criteria
Statistical analysis description: BASFI	
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority <sup>[5]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.39
upper limit	-0.72
Variability estimate	Standard error of the mean
Dispersion value	0.421

Notes:

[5] - BASFI

<b>Statistical analysis title</b>	ASAS Criteria
Statistical analysis description: BASFI	
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority <sup>[6]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	-0.59
Variability estimate	Standard error of the mean
Dispersion value	0.409

Notes:

[6] - BASFI

Statistical analysis title	ASAS Criteria
Statistical analysis description:	
Inflammation	
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority <sup>[7]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-2.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.05
upper limit	-1.28
Variability estimate	Standard error of the mean
Dispersion value	0.448

Notes:

[7] - Inflammation

Statistical analysis title	ASAS Criteria
Statistical analysis description:	
Inflammation	
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority <sup>[8]</sup>
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.66
upper limit	-0.95
Variability estimate	Standard error of the mean
Dispersion value	0.433

Notes:

[8] - Inflammation

## Secondary: Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response

End point title	Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
-----------------	--

**End point description:**

The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis (rad-axSpA): 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. Participants need to score each item with a score from 0 to 10 (NRS). Total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem), with a higher score indicating more severe AS symptom. BASDAI50 represents an improvement of  $\geq 50\%$  of the BASDAI score from baseline.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the nonresponder imputation (NRI) method.

End point type	Secondary
End point timeframe:	
Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of participants				
number (not applicable)	45.3	81.3	75.9	

**Statistical analyses**

<b>Statistical analysis title</b>	BASDAI50
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	5.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.13
upper limit	13.35

<b>Statistical analysis title</b>	BASDAI50
Comparison groups	IXE80Q2W v Placebo

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.75
upper limit	9.45

## Secondary: Change from Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)

End point title	Change from Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
-----------------	--

### End point description:

High sensitivity CRP is the measure of acute phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease activity. High sensitivity CRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: milligram per liter (mg/L)				
least squares mean (standard error)	-5.094 (± 1.3696)	-12.952 (± 1.4666)	-11.074 (± 1.3861)	

## Statistical analyses

Statistical analysis title	High Sensitivity C-Reactive Protein (CRP)
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-7.858
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.729
upper limit	-3.987
Variability estimate	Standard error of the mean
Dispersion value	1.9586

<b>Statistical analysis title</b>	High Sensitivity C-Reactive Protein (CRP)
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-5.979
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.655
upper limit	-2.304
Variability estimate	Standard error of the mean
Dispersion value	1.86

## Secondary: Change from Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)

End point title	Change from Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
-----------------	---

### End point description:

BASMI is a combined index comprising of the following 5 clinical measurements of spinal mobility in patients with radiographic axial spondyloarthritis (rad-axSpA).

- 1) Lateral Spinal Flexion
- 2) Tragus-to-wall distance
- 3) Lumbar Flexion (modified Schober)
- 4) Maximal intermalleolar distance and
- 5) Cervical rotation.

The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient's limitation of movement due to their AS. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Units on a scale				
least squares mean (standard error)	-0.50 ( $\pm$ 0.073)	-0.69 ( $\pm$ 0.080)	-0.73 ( $\pm$ 0.075)	

## Statistical analyses

<b>Statistical analysis title</b>	BASMI
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.062
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.01
Variability estimate	Standard error of the mean
Dispersion value	0.104

<b>Statistical analysis title</b>	BASMI
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.018
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.24

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	-0.04
Variability estimate	Standard error of the mean
Dispersion value	0.099

## Secondary: Change from Baseline in Chest Expansion in Centimeters

End point title	Change from Baseline in Chest Expansion in Centimeters
-----------------	--

End point description:

Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. While patients have their hands resting on or behind the head, the assessor will measure the chest encircled length by centimeter (cm) at the fourth intercostal level anteriorly. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: centimeter (cm)				
least squares mean (standard error)	0.67 (± 0.236)	0.77 (± 0.256)	0.53 (± 0.243)	

## Statistical analyses

Statistical analysis title	Chest Expansion in Centimeters
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.757
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.56
upper limit	0.77
Variability estimate	Standard error of the mean
Dispersion value	0.335

<b>Statistical analysis title</b>	Chest Expansion in Centimeters
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.67
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.77
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.322

## Secondary: Change from Baseline in Occiput to Wall Distance

End point title	Change from Baseline in Occiput to Wall Distance
-----------------	--

### End point description:

The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, Week 64



End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: cm				
least squares mean (standard error)	-0.38 ( $\pm$ 0.235)	-0.78 ( $\pm$ 0.260)	-0.66 ( $\pm$ 0.239)	

## Statistical analyses

<b>Statistical analysis title</b>	Occiput to Wall Distance
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.236
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.07
upper limit	0.27
Variability estimate	Standard error of the mean
Dispersion value	0.338

<b>Statistical analysis title</b>	Occiput to Wall Distance
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.373
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.92
upper limit	0.35
Variability estimate	Standard error of the mean
Dispersion value	0.319

## Secondary: Change from Baseline in Maastricht Ankylosing Spondylitis Enthesitis

## Score (MASES)

End point title	Change from Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
-----------------	--

### End point description:

The MASES is an index used to measure the severity of enthesitis. The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B), and with Baseline MASES score >0. Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	35	29	36	
Units: Units on a scale				
least squares mean (standard error)	-3.48 (± 0.302)	-3.55 (± 0.352)	-3.62 (± 0.315)	

## Statistical analyses

<b>Statistical analysis title</b>	MASES
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.885
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.98
upper limit	0.85
Variability estimate	Standard error of the mean
Dispersion value	0.459

<b>Statistical analysis title</b>	MASES
-----------------------------------	-------

Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.735
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.95
upper limit	0.68
Variability estimate	Standard error of the mean
Dispersion value	0.41

## Secondary: Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score

End point title	Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score
End point description:	
<p>The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.</p> <p>APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B).</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	30	22	30	
Units: Units on a scale				
least squares mean (standard error)	-2.71 ( $\pm$ 0.335)	-3.23 ( $\pm$ 0.388)	-3.34 ( $\pm$ 0.338)	

## Statistical analyses

Statistical analysis title	SPARCC Enthesitis Score
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.294
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.53
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.53
upper limit	0.47
Variability estimate	Standard error of the mean
Dispersion value	0.501

<b>Statistical analysis title</b>	SPARCC Enthesitis Score
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.164
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.54
upper limit	0.27
Variability estimate	Standard error of the mean
Dispersion value	0.453

## Secondary: Change from Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints

End point title	Change from Baseline in Severity of Peripheral Arthritis by Tender Joint Count (TJC) Score of 46 Joints
-----------------	---

### End point description:

The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the body). The 46 joints were assessed and classified as tender or not tender. Sum of all joints checked to be tender/painful divided by number of evaluable joints which was multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B), and with baseline TJC >0. Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	23	27	33	
Units: Units on a scale				
least squares mean (standard error)	-4.0 ( $\pm$ 0.85)	-6.1 ( $\pm$ 0.76)	-5.3 ( $\pm$ 0.74)	

## Statistical analyses

Statistical analysis title	TJC Score
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	50
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.063
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	1.1

Statistical analysis title	TJC Score
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	56
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.211
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	0.7
Variability estimate	Standard error of the mean
Dispersion value	1.02

## Secondary: Change from Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints

End point title	Change from Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) Score of 44 Joints
-----------------	--

### End point description:

The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the body). The 44 joints were assessed and classified as swollen or not swollen. Sum of all joints checked to be swollen divided by number of evaluable joints which was multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B), and with baseline SJC >0. Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	15	16	21	
Units: Units on a scale				
least squares mean (standard error)	-2.7 (± 0.73)	-3.6 (± 0.67)	-3.9 (± 0.59)	

## Statistical analyses

Statistical analysis title	SJC Score
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	31
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.334
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	0.9
Variability estimate	Standard error of the mean
Dispersion value	0.9

<b>Statistical analysis title</b>	SJC Score
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	36
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.168
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.88

### Secondary: Percentage of Participants with Anterior Uveitis or Uveitis Flares

End point title	Percentage of Participants with Anterior Uveitis or Uveitis Flares
End point description:	
Anterior uveitis is an inflammation of the middle layer of the eye, which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.	
APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B), and regardless of history of anterior uveitis.	
End point type	Secondary
End point timeframe:	
Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: Percentage of Participants				
number (not applicable)	5.7	4.2	5.6	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in the Fatigue Numeric Rating Scale (NRS) Score

End point title	Change from Baseline in the Fatigue Numeric Rating Scale (NRS) Score
End point description:	
<p>The fatigue severity NRS is a participant administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the 1 number that describes their worst level of fatigue during the previous 24 hours. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.</p> <p>APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	-3.5 (± 0.28)	-4.2 (± 0.31)	-4.3 (± 0.29)	

## Statistical analyses

<b>Statistical analysis title</b>	NRS Score
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.4

<b>Statistical analysis title</b>	NRS Score
Comparison groups	IXE80Q2W v Placebo



Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.047
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	0
Variability estimate	Standard error of the mean
Dispersion value	0.38

### Secondary: Change from Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)

End point title	Change from Baseline on the Quick Inventory of Depressive Symptomatology Self-Report-16 (QIDS-SR16)
-----------------	---

#### End point description:

The 16-item QIDS-SR16 version is a widely used validated scale designed to assess the severity of depressive symptoms. The participant was asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27, where higher scores indicate higher severity of symptoms. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	-2.80 (± 0.342)	-3.68 (± 0.362)	-3.28 (± 0.344)	

### Statistical analyses

Statistical analysis title	QIDS-SR16
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.068
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.83
upper limit	0.06
Variability estimate	Standard error of the mean
Dispersion value	0.479

<b>Statistical analysis title</b>	QIDS-SR16
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.307
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	0.44
Variability estimate	Standard error of the mean
Dispersion value	0.465

## **Secondary: Change from Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score**

End point title	Change from Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
-----------------	---

### **End point description:**

The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well-being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	10.6934 ( $\pm$ 1.0366)	13.2954 ( $\pm$ 1.1210)	13.1030 ( $\pm$ 1.0457)	

### Statistical analyses

Statistical analysis title	Physical Component Summary (PCS) Score
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.079
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	2.6021
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3011
upper limit	5.5053
Variability estimate	Standard error of the mean
Dispersion value	1.4684

Statistical analysis title	Physical Component Summary (PCS) Score
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.087
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	2.4096
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3541
upper limit	5.1734

Variability estimate	Standard error of the mean
Dispersion value	1.3978

## Secondary: Change from Baseline in SF-36 Mental Component Summary (MCS) Score

End point title	Change from Baseline in SF-36 Mental Component Summary (MCS) Score
-----------------	--

### End point description:

The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well-being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, Week 64

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	2.3396 ( $\pm$ 0.8314)	3.1766 ( $\pm$ 0.8968)	4.6404 ( $\pm$ 0.8369)	

## Statistical analyses

<b>Statistical analysis title</b>	Mental Component Summary (MCS) Score
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.477
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.837
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4864
upper limit	3.1605

Variability estimate	Standard error of the mean
Dispersion value	1.1752

<b>Statistical analysis title</b>	Mental Component Summary (MCS) Score
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.042
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	2.3009
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.088
upper limit	4.5138
Variability estimate	Standard error of the mean
Dispersion value	1.1192

## Secondary: Change from Baseline in ASAS Health Index (ASAS HI)

End point title	Change from Baseline in ASAS Health Index (ASAS HI)
-----------------	---

End point description:

The ASAS Health Index (ASAS HI) is a disease specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17 item instrument has scores ranging from 0 (good Health) to 17 (poor Health). Each item consists of 1 question that the patient needs to respond to with either "I agree" (score 1) or "I do not agree (score 0)." A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the modified baseline observation carried forward (mBOCF) method.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 64

<b>End point values</b>	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	-3.64 (± 0.370)	-4.64 (± 0.393)	-4.37 (± 0.368)	

### Statistical analyses

<b>Statistical analysis title</b>	ASAS HI
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.058
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.02
upper limit	0.04
Variability estimate	Standard error of the mean
Dispersion value	0.52

<b>Statistical analysis title</b>	ASAS HI
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.147
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.71
upper limit	0.26
Variability estimate	Standard error of the mean
Dispersion value	0.497

### Secondary: Change from Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK population-based index score

End point title	Change from Baseline in the European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) UK population-based index score
-----------------	--

**End point description:**

The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0- to 100-mm visual analog scale (VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using the mBOCF method.

End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	0.2459 ( $\pm$ 0.0237)	0.2877 ( $\pm$ 0.0252)	0.2847 ( $\pm$ 0.0235)	

**Statistical analyses**

Statistical analysis title	EQ-5D-5L UK Population-based Index Score
Comparison groups	Placebo v IXE80Q4W
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.213
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.0418
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0329
upper limit	0.1164
Variability estimate	Standard error of the mean
Dispersion value	0.0334

Statistical analysis title	EQ-5D-5L UK Population-based Index Score
Comparison groups	Placebo v IXE80Q2W

Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.225
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	0.0388
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.0324
upper limit	0.1101
Variability estimate	Standard error of the mean
Dispersion value	0.0319

### Secondary: Change from Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores

End point title	Change from Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
End point description:	
<p>The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100, with higher scores indicating greater impairment and less productivity. LS mean was determined by ANCOVA.</p> <p>APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using MBOCF.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)				
Overall Work Impairment Score	-28.73 (± 3.677)	-40.94 (± 3.752)	-36.53 (± 3.221)	
Percentage of Activity Impairment	-32.96 (± 3.099)	-43.58 (± 3.329)	-40.10 (± 3.115)	

### Statistical analyses



<b>Statistical analysis title</b>	WPAI-SpA Scores
Statistical analysis description:	
Overall Work Impairment Score	
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority <sup>[9]</sup>
P-value	= 0.016
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-12.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.04
upper limit	-2.38
Variability estimate	Standard error of the mean
Dispersion value	4.939

Notes:

[9] - Overall Work Impairment Score

<b>Statistical analysis title</b>	WPAI-SpA Scores
Statistical analysis description:	
Overall Work Impairment Score	
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority <sup>[10]</sup>
P-value	= 0.092
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-7.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.91
upper limit	1.31
Variability estimate	Standard error of the mean
Dispersion value	4.578

Notes:

[10] - Overall Work Impairment Score

<b>Statistical analysis title</b>	WPAI-SpA Scores
Statistical analysis description:	
Percentage of Activity Impairment	
Comparison groups	IXE80Q4W v Placebo

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority <sup>[11]</sup>
P-value	= 0.017
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-10.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.28
upper limit	-1.95
Variability estimate	Standard error of the mean
Dispersion value	4.383

Notes:

[11] - Percentage of Activity Impairment

<b>Statistical analysis title</b>	WPAI-SpA Scores
Statistical analysis description: Percentage of Activity Impairment	
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority <sup>[12]</sup>
P-value	= 0.091
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-7.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.44
upper limit	1.16
Variability estimate	Standard error of the mean
Dispersion value	4.199

Notes:

[12] - Percentage of Activity Impairment

## Secondary: Change from Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)

End point title	Change from Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
-----------------	---

End point description:

JSEQ is a 4 item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Patients report the numbers of days they experience each of these problems in the past month on a 6 point Likert Scale ranging from 0 = "no days" to 5 = "22-30 days". The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LS mean was determined by ANCOVA with treatment, geographic region, originating study, baseline value and Week 24 value as fixed factors.

APD: Participants who achieved a state of sustained remission and were randomized to 40-week double-blind placebo controlled RWR period (Group B). Missing data was imputed using mBOCF method.

End point type	Secondary
End point timeframe:	
Baseline, Week 64	

End point values	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	53	48	54	
Units: units on a scale				
least squares mean (standard error)	-3.6 ( $\pm$ 0.47)	-4.0 ( $\pm$ 0.50)	-3.8 ( $\pm$ 0.47)	

## Statistical analyses

Statistical analysis title	JSEQ
Comparison groups	IXE80Q4W v Placebo
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.531
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	0.9
Variability estimate	Standard error of the mean
Dispersion value	0.66

Statistical analysis title	JSEQ
Comparison groups	IXE80Q2W v Placebo
Number of subjects included in analysis	107
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.743
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	1

Variability estimate	Standard error of the mean
Dispersion value	0.62

### Secondary: Percentage of Participants with No New Syndesmophyte Formation

End point title	Percentage of Participants with No New Syndesmophyte Formation
-----------------	--

End point description:

Percentage of participants with no new syndesmophyte formation was measured using the average score of 2 selected readers of 3 readers.

APD: Ixekizumab structure population who have been treated with Ixekizumab for at least 24 months

End point type	Secondary
----------------	-----------

End point timeframe:

Week 56

End point values	IXE80Q4W	IXE80Q2W		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	115	115		
Units: Percentage of participants				
number (not applicable)	80.9	87.8		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Anti-Ixekizumab Antibodies

End point title	Percentage of Participants with Anti-Ixekizumab Antibodies
-----------------	--

End point description:

A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a  $\geq 4$ -fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of  $\geq 1:10$ . Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

APD: All randomized participants from Group B, who received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 64

<b>End point values</b>	Placebo	IXE80Q4W	IXE80Q2W	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	45	43	51	
Units: Percentage of participants				
number (not applicable)	4.7	2.0	20.0	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline, up to 3 Years

Adverse event reporting additional description:

All randomized participants. There are gender specific adverse events, only occurring in male or female participants. The number of participants exposed has been adjusted accordingly.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

### Reporting groups

Reporting group title	IXE80Q2W-lead-in period
Reporting group description: -	
Reporting group title	IXE80Q4W-lead-in period
Reporting group description: -	
Reporting group title	IXE80Q2W-group A extension period
Reporting group description: -	
Reporting group title	IXE80Q4W-group A extension period
Reporting group description: -	
Reporting group title	IXE80Q2W-randomized withdrawal extension period
Reporting group description: -	
Reporting group title	IXE80Q4W-randomized withdrawal extension period
Reporting group description: -	
Reporting group title	PBO-randomized withdrawal extension period
Reporting group description: -	
Reporting group title	IXE80Q2W/IXE80Q2W-retreatment extension period
Reporting group description: -	
Reporting group title	IXE80Q4W/IXE80Q4W-retreatment extension period
Reporting group description: -	
Reporting group title	PBO/IXE80Q2W-retreatment extension period
Reporting group description: -	
Reporting group title	PBO/IXE80Q4W-retreatment extension period
Reporting group description: -	

Serious adverse events	IXE80Q2W-lead-in period	IXE80Q4W-lead-in period	IXE80Q2W-group A extension period
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 423 (2.84%)	11 / 348 (3.16%)	11 / 318 (3.46%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
anal cancer			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
benign lung neoplasm			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
breast cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic lymphocytic leukaemia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[1]</sup>	1 / 130 (0.77%)	0 / 92 (0.00%)	0 / 95 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian germ cell teratoma benign			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[2]</sup>	0 / 130 (0.00%)	0 / 92 (0.00%)	0 / 95 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
papillary thyroid cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Vascular disorders			
venous thrombosis limb			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
death			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
soft tissue inflammation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
haemothorax			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
major depression			
alternative dictionary used: MedDRA 23.0			



subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicidal ideation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
clavicle fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
compression fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
concussion			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
contusion			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ilium fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ligament sprain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
limb injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lumbar vertebral fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

pneumothorax traumatic alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 423 (0.00%) 0 / 0 0 / 0	0 / 348 (0.00%) 0 / 0 0 / 0	1 / 318 (0.31%) 0 / 1 0 / 0
rib fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 423 (0.00%) 0 / 0 0 / 0	0 / 348 (0.00%) 0 / 0 0 / 0	1 / 318 (0.31%) 0 / 1 0 / 0
spinal column injury alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 423 (0.00%) 0 / 0 0 / 0	1 / 348 (0.29%) 0 / 1 0 / 0	0 / 318 (0.00%) 0 / 0 0 / 0
synovial rupture alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 423 (0.00%) 0 / 0 0 / 0	0 / 348 (0.00%) 0 / 0 0 / 0	1 / 318 (0.31%) 0 / 1 0 / 0
Cardiac disorders cardiac failure acute alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 423 (0.00%) 0 / 0 0 / 0	0 / 348 (0.00%) 0 / 0 0 / 0	0 / 318 (0.00%) 0 / 0 0 / 0
myocardial infarction alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 423 (0.00%) 0 / 0 0 / 0	0 / 348 (0.00%) 0 / 0 0 / 0	0 / 318 (0.00%) 0 / 0 0 / 0
Nervous system disorders hypoglycaemic unconsciousness alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myelopathy alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radiculopathy alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders iritidocyclitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders colitis ulcerative alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	2 / 423 (0.47%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
inguinal hernia alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
strangulated umbilical hernia alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
subcutaneous emphysema			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urticaria			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
calculus urinary			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ureterolithiasis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthritis			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
back pain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	2 / 348 (0.57%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal ligament ossification			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
temporomandibular joint syndrome			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tenosynovitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
cellulitis			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic tonsillitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
clostridium difficile colitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
orchitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[3]</sup>	0 / 293 (0.00%)	1 / 256 (0.39%)	0 / 223 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory tract infection viral			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

urinary tract infection alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders hyperglycaemia alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	0 / 318 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperkalaemia alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	1 / 318 (0.31%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	IXE80Q4W-group A extension period	IXE80Q2W- randomized withdrawal extension period	IXE80Q4W- randomized withdrawal extension period
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 255 (4.31%)	2 / 54 (3.70%)	2 / 47 (4.26%)
number of deaths (all causes)	2	0	0
number of deaths resulting from adverse events	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps) anal cancer alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
benign lung neoplasm alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



breast cancer alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic lymphocytic leukaemia alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian cancer alternative dictionary used: MedDRA 23.0 subjects affected / exposed <sup>[1]</sup>	0 / 68 (0.00%)	0 / 14 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian germ cell teratoma benign alternative dictionary used: MedDRA 23.0 subjects affected / exposed <sup>[2]</sup>	0 / 68 (0.00%)	0 / 14 (0.00%)	1 / 10 (10.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
papillary thyroid cancer alternative dictionary used: MedDRA 23.0 subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders venous thrombosis limb alternative dictionary used: MedDRA 23.0 subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions death			

alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
soft tissue inflammation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
haemothorax			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
major depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicidal ideation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
blood creatine phosphokinase increased			

alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
clavicle fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
compression fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	1 / 47 (2.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
concussion			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
contusion			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ilium fracture			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ligament sprain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
limb injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lumbar vertebral fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumothorax traumatic			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

spinal column injury alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
synovial rupture alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
cardiac failure acute alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myocardial infarction alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
hypoglycaemic unconsciousness alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
myelopathy alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	1 / 54 (1.85%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
radiculopathy alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
iridocyclitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
colitis ulcerative			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	2 / 255 (0.78%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
inguinal hernia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
strangulated umbilical hernia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
subcutaneous emphysema			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urticaria			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
calculus urinary			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ureterolithiasis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthritis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
back pain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	2 / 255 (0.78%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal ligament ossification alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
temporomandibular joint syndrome alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tenosynovitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
cellulitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic tonsillitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	1 / 54 (1.85%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
clostridium difficile colitis alternative dictionary used: MedDRA 23.0			



subjects affected / exposed	0 / 255 (0.00%)	1 / 54 (1.85%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
orchitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[3]</sup>	0 / 187 (0.00%)	0 / 40 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory tract infection viral			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 255 (0.39%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
urinary tract infection			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
hyperglycaemia			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperkalaemia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 255 (0.00%)	0 / 54 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	PBO-randomized withdrawal extension period	IXE80Q2W/IXE80Q2 W-retreatment extension period	IXE80Q4W/IXE80Q4 W-retreatment extension period
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 53 (1.89%)	1 / 6 (16.67%)	0 / 5 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
anal cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
benign lung neoplasm			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
breast cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic lymphocytic leukaemia			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[1]</sup>	0 / 15 (0.00%)	0 / 2 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ovarian germ cell teratoma benign			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[2]</sup>	0 / 15 (0.00%)	0 / 2 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
papillary thyroid cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
venous thrombosis limb			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
death			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
soft tissue inflammation			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	1 / 53 (1.89%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
haemothorax			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
major depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicidal ideation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

clavicle fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
compression fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
concussion alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
contusion alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
femur fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ilium fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ligament sprain alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
limb injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
lumbar vertebral fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pneumothorax traumatic			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal column injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

synovial rupture alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 53 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
Cardiac disorders cardiac failure acute alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 53 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
myocardial infarction alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 53 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
Nervous system disorders hypoglycaemic unconsciousness alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 53 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
myelopathy alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 53 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
radiculopathy alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 53 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
Eye disorders iritidocyclitis			

alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
colitis ulcerative			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
inguinal hernia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
strangulated umbilical hernia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
subcutaneous emphysema			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urticaria			
alternative dictionary used: MedDRA 23.0			



subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
calculus urinary			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ureterolithiasis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthritis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
back pain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
osteoarthritis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
spinal ligament ossification			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
temporomandibular joint syndrome alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
tenosynovitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
cellulitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
chronic tonsillitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
clostridium difficile colitis alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 53 (0.00%)	1 / 6 (16.67%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
orchitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[3]</sup>	0 / 38 (0.00%)	0 / 4 (0.00%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
respiratory tract infection viral			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
sepsis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urinary tract infection			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
hyperglycaemia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
hyperkalaemia			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 53 (0.00%)	0 / 6 (0.00%)	0 / 5 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	PBO/IXE80Q2W- retreatment extension period	PBO/IXE80Q4W- retreatment extension period	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
anal cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
benign lung neoplasm			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
breast cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
chronic lymphocytic leukaemia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ovarian cancer			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed <sup>[1]</sup>	0 / 2 (0.00%)	0 / 2 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ovarian germ cell teratoma benign			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[2]</sup>	0 / 2 (0.00%)	0 / 2 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
papillary thyroid cancer			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
venous thrombosis limb			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
death			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
soft tissue inflammation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
haemothorax			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
major depression			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
suicidal ideation			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
blood creatine phosphokinase increased			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
clavicle fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
compression fracture			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
concussion			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
contusion			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
femur fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ilium fracture			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ligament sprain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
limb injury			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

lumbar vertebral fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	
meniscus injury alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	
pneumothorax traumatic alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	
rib fracture alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	
spinal column injury alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	
synovial rupture alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 9 (0.00%) 0 / 0 0 / 0	0 / 10 (0.00%) 0 / 0 0 / 0	
Cardiac disorders cardiac failure acute alternative dictionary used: MedDRA 23.0			



subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myocardial infarction			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
hypoglycaemic unconsciousness			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
myelopathy			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
radiculopathy			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
iritidocyclitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
colitis ulcerative			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
inguinal hernia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
strangulated umbilical hernia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
subcutaneous emphysema			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urticaria			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
calculus urinary			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ureterolithiasis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
arthritis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
back pain			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
osteoarthritis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
spinal ligament ossification			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
temporomandibular joint syndrome			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
tenosynovitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
cellulitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
chronic tonsillitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
clostridium difficile colitis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
influenza			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
orchitis			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed <sup>[3]</sup>	0 / 7 (0.00%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
respiratory tract infection viral			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
sepsis			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
hyperglycaemia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperkalaemia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 9 (0.00%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>IXE80Q2W-lead-in period</b>	<b>IXE80Q4W-lead-in period</b>	<b>IXE80Q2W-group A extension period</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	100 / 423 (23.64%)	70 / 348 (20.11%)	65 / 318 (20.44%)
Investigations			
neutrophil count decreased			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	1 / 423 (0.24%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences (all)	1	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
ovarian germ cell teratoma benign			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed <sup>[4]</sup>	0 / 130 (0.00%)	0 / 92 (0.00%)	0 / 95 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
contusion			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	2 / 348 (0.57%)	1 / 318 (0.31%)
occurrences (all)	0	2	1
foreign body in eye			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	0 / 348 (0.00%)	0 / 318 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
leukopenia			
alternative dictionary used: MedDRA 23.0			
subjects affected / exposed	0 / 423 (0.00%)	1 / 348 (0.29%)	2 / 318 (0.63%)
occurrences (all)	0	1	2
Eye disorders			
iritidocyclitis			
alternative dictionary used: MedDRA 23.0			

subjects affected / exposed occurrences (all)	5 / 423 (1.18%) 5	8 / 348 (2.30%) 8	10 / 318 (3.14%) 11
Gastrointestinal disorders diarrhoea alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	10 / 423 (2.36%) 10	3 / 348 (0.86%) 4	4 / 318 (1.26%) 5
Skin and subcutaneous tissue disorders rash alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	5 / 423 (1.18%) 5	1 / 348 (0.29%) 2	3 / 318 (0.94%) 3
Musculoskeletal and connective tissue disorders back pain alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	15 / 423 (3.55%) 15	10 / 348 (2.87%) 10	3 / 318 (0.94%) 3
Infections and infestations gastrointestinal viral infection alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  nasopharyngitis alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  pharyngitis alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  upper respiratory tract infection alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 423 (0.00%) 0  39 / 423 (9.22%) 41  9 / 423 (2.13%) 10  22 / 423 (5.20%) 24	0 / 348 (0.00%) 0  27 / 348 (7.76%) 28  5 / 348 (1.44%) 6  15 / 348 (4.31%) 18	0 / 318 (0.00%) 0  27 / 318 (8.49%) 28  7 / 318 (2.20%) 7  13 / 318 (4.09%) 14
Metabolism and nutrition disorders			

glucose tolerance impaired alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 423 (0.00%) 0	0 / 348 (0.00%) 0	0 / 318 (0.00%) 0
---	----------------------	----------------------	----------------------

<b>Non-serious adverse events</b>	IXE80Q4W-group A extension period	IXE80Q2W- randomized withdrawal extension period	IXE80Q4W- randomized withdrawal extension period
Total subjects affected by non-serious adverse events subjects affected / exposed	52 / 255 (20.39%)	16 / 54 (29.63%)	8 / 47 (17.02%)
Investigations neutrophil count decreased alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 255 (0.00%) 0	0 / 54 (0.00%) 0	1 / 47 (2.13%) 2
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ovarian germ cell teratoma benign alternative dictionary used: MedDRA 23.0 subjects affected / exposed <sup>[4]</sup> occurrences (all)	0 / 68 (0.00%) 0	0 / 14 (0.00%) 0	1 / 10 (10.00%) 1
Injury, poisoning and procedural complications contusion alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  foreign body in eye alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 255 (0.00%) 0  0 / 255 (0.00%) 0	0 / 54 (0.00%) 0  0 / 54 (0.00%) 0	1 / 47 (2.13%) 1  0 / 47 (0.00%) 0
Blood and lymphatic system disorders leukopenia alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 255 (0.00%) 0	0 / 54 (0.00%) 0	0 / 47 (0.00%) 0
Eye disorders			



iridocyclitis alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	7 / 255 (2.75%) 8	2 / 54 (3.70%) 3	2 / 47 (4.26%) 2
Gastrointestinal disorders diarrhoea alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	6 / 255 (2.35%) 6	3 / 54 (5.56%) 3	0 / 47 (0.00%) 0
Skin and subcutaneous tissue disorders rash alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	1 / 255 (0.39%) 1	1 / 54 (1.85%) 3	0 / 47 (0.00%) 0
Musculoskeletal and connective tissue disorders back pain alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	3 / 255 (1.18%) 3	3 / 54 (5.56%) 3	1 / 47 (2.13%) 1
Infections and infestations gastrointestinal viral infection alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  nasopharyngitis alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  pharyngitis alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  upper respiratory tract infection alternative dictionary used: MedDRA 23.0	0 / 255 (0.00%) 0  26 / 255 (10.20%) 32  9 / 255 (3.53%) 9	0 / 54 (0.00%) 0  4 / 54 (7.41%) 6  0 / 54 (0.00%) 0	0 / 47 (0.00%) 0  2 / 47 (4.26%) 3  0 / 47 (0.00%) 0

subjects affected / exposed occurrences (all)	7 / 255 (2.75%) 7	4 / 54 (7.41%) 4	2 / 47 (4.26%) 3
Metabolism and nutrition disorders glucose tolerance impaired alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 255 (0.00%) 0	0 / 54 (0.00%) 0	0 / 47 (0.00%) 0

<b>Non-serious adverse events</b>	PBO-randomized withdrawal extension period	IXE80Q2W/IXE80Q2 W-retreatment extension period	IXE80Q4W/IXE80Q4 W-retreatment extension period
Total subjects affected by non-serious adverse events subjects affected / exposed	16 / 53 (30.19%)	0 / 6 (0.00%)	4 / 5 (80.00%)
Investigations neutrophil count decreased alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	1 / 5 (20.00%) 2
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ovarian germ cell teratoma benign alternative dictionary used: MedDRA 23.0 subjects affected / exposed <sup>[4]</sup> occurrences (all)	0 / 15 (0.00%) 0	0 / 2 (0.00%) 0	0 / 1 (0.00%) 0
Injury, poisoning and procedural complications contusion alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  foreign body in eye alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	1 / 53 (1.89%) 1  0 / 53 (0.00%) 0	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0	0 / 5 (0.00%) 0  1 / 5 (20.00%) 1
Blood and lymphatic system disorders leukopenia alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	1 / 5 (20.00%) 1

<p>Eye disorders</p> <p>iridocyclitis</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 53 (5.66%)</p> <p>3</p>	<p>0 / 6 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>Gastrointestinal disorders</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 53 (1.89%)</p> <p>1</p>	<p>0 / 6 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>Skin and subcutaneous tissue disorders</p> <p>rash</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 53 (5.66%)</p> <p>3</p>	<p>0 / 6 (0.00%)</p> <p>0</p>	<p>0 / 5 (0.00%)</p> <p>0</p>
<p>Musculoskeletal and connective tissue disorders</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 53 (3.77%)</p> <p>2</p>	<p>0 / 6 (0.00%)</p> <p>0</p>	<p>1 / 5 (20.00%)</p> <p>1</p>
<p>Infections and infestations</p> <p>gastrointestinal viral infection</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nasopharyngitis</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pharyngitis</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>upper respiratory tract infection</p> <p>alternative dictionary used: MedDRA 23.0</p>	<p>0 / 53 (0.00%)</p> <p>0</p> <p>7 / 53 (13.21%)</p> <p>8</p> <p>3 / 53 (5.66%)</p> <p>3</p>	<p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p> <p>0 / 6 (0.00%)</p> <p>0</p>	<p>1 / 5 (20.00%)</p> <p>1</p> <p>1 / 5 (20.00%)</p> <p>1</p> <p>0 / 5 (0.00%)</p> <p>0</p>

subjects affected / exposed occurrences (all)	2 / 53 (3.77%) 2	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0
Metabolism and nutrition disorders glucose tolerance impaired alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 53 (0.00%) 0	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0

<b>Non-serious adverse events</b>	PBO/IXE80Q2W- retreatment extension period	PBO/IXE80Q4W- retreatment extension period	
Total subjects affected by non-serious adverse events subjects affected / exposed	2 / 9 (22.22%)	1 / 10 (10.00%)	
Investigations neutrophil count decreased alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) ovarian germ cell teratoma benign alternative dictionary used: MedDRA 23.0 subjects affected / exposed <sup>[4]</sup> occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	
Injury, poisoning and procedural complications contusion alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)  foreign body in eye alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1  0 / 9 (0.00%) 0	0 / 10 (0.00%) 0  0 / 10 (0.00%) 0	
Blood and lymphatic system disorders leukopenia alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	0 / 10 (0.00%) 0	

<p>Eye disorders</p> <p>iridocyclitis</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 9 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	
<p>Gastrointestinal disorders</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 9 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	
<p>Skin and subcutaneous tissue disorders</p> <p>rash</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 9 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 9 (11.11%)</p> <p>1</p>	<p>0 / 10 (0.00%)</p> <p>0</p>	
<p>Infections and infestations</p> <p>gastrointestinal viral infection</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nasopharyngitis</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pharyngitis</p> <p>alternative dictionary used: MedDRA 23.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>upper respiratory tract infection</p> <p>alternative dictionary used: MedDRA 23.0</p>	<p>0 / 9 (0.00%)</p> <p>0</p> <p>1 / 9 (11.11%)</p> <p>1</p> <p>0 / 9 (0.00%)</p> <p>0</p>	<p>0 / 10 (0.00%)</p> <p>0</p> <p>0 / 10 (0.00%)</p> <p>0</p> <p>0 / 10 (0.00%)</p> <p>0</p>	

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Metabolism and nutrition disorders glucose tolerance impaired alternative dictionary used: MedDRA 23.0 subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	

Notes:

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported